Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib in Advanced TNBC
NCT03394287Phase 2Completed
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen Memorial Hospital. Started Jan 2018; status: completed.
02
Drugs
camrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03394287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03394287.